Autolus Therapeutics plc ADR (AUTL)
NASDAQ: AUTLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AUTL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $241.65M
- EPS (TTM)
- -$0.96
- Dividend yield
- None
- 52-week range
- 0.896 – 2.58
- Day range
- 0.8963 – 0.9797
- Volume / Avg
- 3.90M / 2.07M
- Beta
- —
- Shares outstanding
- 266.34M
52-week range
AUTL stock today
Autolus Therapeutics (AUTL) closed at $0.9073 on Nov 20, down 7.38% (-$0.0723), versus the S&P 500's 3.70% decline. At this level, AUTL sits near the bottom of its 52-week range of $0.896 to $2.58: 64.8% below the high, set on Aug 19, 2026 and 1.3% above the low. AUTL is down 54.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 26.2%.
Autolus Therapeutics has posted a net loss over the last twelve months (EPS of -$0.96), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Autolus Therapeutics
Company profileAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Christian Martin Itin Ph.D.
- Headquarters
- London
- Employees
- 752
- IPO year
- 2018
- Website
- autolus.com
Financial highlights
Full financialsIn fiscal 2025, Autolus Therapeutics generated $75.4 million in revenue, up 644.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Autolus Therapeutics reported a net loss of $287.5 million, compared with a loss of $220.7 million a year earlier. Gross margin was -27.8% (down from -12.5%) and operating margin -358.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $75.39M | $10.12M | $1.70M | — | — |
| Growth | +644.94% | +496.00% | — | — | — |
| Net income | $-287.53M | $-220.66M | $-208.38M | $-148.84M | $-142.10M |
| EPS (diluted) | $-1.08 | $-0.86 | $-1.20 | $-1.57 | $-1.97 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$8.36+821.42%
- Strong buy 1
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.21 vs $-0.21
- Surprise
- 0.00%
AUTL news
All AUTL news- Autolus (AUTL) Q3 2026 Earnings Call TranscriptNasdaq
- Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026GlobeNewswire
- Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswire
- Autolus Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswire
- Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026GlobeNewswire
- Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026GlobeNewswire
Autolus Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PLXProtalix BioTherapeutics Inc. (DE) | 2.90 | -5.23% | $244.52M | vs AUTL |
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs AUTL |
| EDITEditas Medicine Inc. | 1.64 | -4.09% | $253.12M | vs AUTL |
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs AUTL |
| SCTXScribe Therapeutics Inc. | 12.07 | -8.70% | $228.58M | vs AUTL |
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs AUTL |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs AUTL |
| ALLOAllogene Therapeutics Inc. | 0.6277 | -5.88% | $217.48M | vs AUTL |
Indexes, lists and sector
Autolus Therapeutics stock FAQ
What is Autolus Therapeutics's stock price today?
AUTL last traded at $0.9073 as of Nov 20, 4:00 PM EST, down 7.38% on the day. Prices are delayed at least 15 minutes.
Who is Autolus Therapeutics's CEO?
Dr. Christian Martin Itin Ph.D. is the chief executive officer of Autolus Therapeutics plc ADR, which has about 752 employees.
What is the AUTL 52-week high?
The 52-week high for AUTL is $2.58 and the 52-week low is $0.896. The stock is currently 64.8% below its high.